GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3295
- Registration Number
- NCT04925752
- Locations
- 🇺🇸
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles, California, United States
🇺🇸Howard Brown Health Center, Chicago, Illinois, United States
🇺🇸The Crofoot Research Center, INC, Houston, Texas, United States
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT04892446
- Locations
- 🇺🇸
US Oncology, Inc., IRB, Fairfax, Virginia, United States
🇺🇸US San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 103
- Registration Number
- NCT04891770
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇩🇰Odense University Hospital, Odense, Denmark
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 193
- Registration Number
- NCT04854499
- Locations
- 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
🇧🇪Algemeen Ziekenhuis Klina, Brasschaat, Belgium
Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04827589
Study of Magrolimab in Patients With Solid Tumors
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT04827576
- Locations
- 🇺🇸
Tallahassee Memorial Healthcare Cancer Center, Tallahassee, Florida, United States
🇺🇸University of Miami, Deerfield Beach, Florida, United States
🇺🇸Virginia Piper Cancer Center (Alliant Health), Saint Paul, Minnesota, United States
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT04811040
- Locations
- 🇺🇸
Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The Brody School of Medicine at East Carolina University, ECU Adult Specialty Care, Greenville, North Carolina, United States
🇺🇸Be Well Medical Center, Berkley, Michigan, United States
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT04809623
- Locations
- 🇺🇸
Wallace Rheumatic Studies Center, LLC, Beverly Hills, California, United States
🇺🇸DJL Clinical Research, PLLC, Charlotte, North Carolina, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT04778397
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT04778410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States